Prophylactic Effects of Agomelatine for Poststroke Depression
Status:
Not yet recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
The incidence of depression in stroke patients with frontal lobe involvement was reported to
be as high as 42%. Agomelatin, a type 1/2 melatonin receptor agonist and serotonin 2C
receptor antagonist, is effective in treatment of depression, but whether it can prevent
poststroke depression (PSD) remains unknown. The PRAISED trial is a multicenter, randomized,
double-blind trial and is designed to evaluate the efficacy and safety of agomelatine in the
prevention of PSD in stroke patients with frontal lobe involvement. The primary outcome is
the rate of post-stroke depression for 180 days.